肺炎克雷伯菌菌株中耐抑制剂TEM（IRT）β-内酰胺酶的首次鉴定。
First characterization of inhibitor-resistant TEM (IRT) beta-lactamases in Klebsiella pneumoniae strains.
作者信息
Lemozy J, Sirot D, Chanal C, Huc C, Labia R, Dabernat H, Sirot J
机构信息
Laboratoire de Microbiologie, CHR PURPAN, Toulouse, France.
出版信息
Antimicrob Agents Chemother. 1995 Nov;39(11):2580-2. doi: 10.1128/AAC.39.11.2580.
Abstract
Two clinical strains of Klebsiella pneumoniae, TP 01 and TP 02, presented resistance to amoxicillin-clavulanate and were fully susceptible to cephalothin. These strains produced two beta-lactamases, SHV-1 and a TEM enzyme with a pI of 5.2. The previously described changes Arg-244-->Cys and Arg-244-->Ser in IRT-1 and IRT-2 (A. Belaaouaj, C. Lapoumeroulie, M. M. Caniça, G. Vedel, P. Nevot, R. Krishnamoorthy, and G. Paul, FEMS Microbiol. Lett. 120:75-80, 1994) were found in TEM enzymes from the TP 01 and TP 02 strains, respectively. This is the first report of inhibitor-resistant TEM (IRT) in species other than Escherichia coli from the family Enterobacteriaceae.
摘要
两株肺炎克雷伯菌临床菌株TP 01和TP 02对阿莫西林-克拉维酸耐药，但对头孢噻吩完全敏感。这些菌株产生了两种β-内酰胺酶，即SHV-1和一种等电点为5.2的TEM酶。在TP 01和TP 02菌株的TEM酶中分别发现了先前描述的IRT-1和IRT-2中的Arg-244→Cys和Arg-244→Ser变化（A. Belaaouaj、C. Lapoumeroulie、M. M. Caniça、G. Vedel、P. Nevot、R. Krishnamoorthy和G. Paul，《FEMS微生物学快报》120:75-80，1994年）。这是肠杆菌科中除大肠杆菌外其他物种中耐抑制剂TEM（IRT）的首次报道。
相似文献
1
First characterization of inhibitor-resistant TEM (IRT) beta-lactamases in Klebsiella pneumoniae strains.
Antimicrob Agents Chemother. 1995 Nov;39(11):2580-2. doi: 10.1128/AAC.39.11.2580.
2
Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.
Antimicrob Agents Chemother. 1995 Nov;39(11):2478-83. doi: 10.1128/AAC.39.11.2478.
3
Reduced susceptibility to co-amoxiclav in Escherichia coli, Salmonella typhimurium and Klebsiella pneumoniae isolated in Romania between 1985 and 1993.
J Antimicrob Chemother. 1997 Jan;39(1):103-6. doi: 10.1093/jac/39.1.103.
4
beta-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa.
Antimicrob Agents Chemother. 1998 Jun;42(6):1350-4. doi: 10.1128/AAC.42.6.1350.
5
Analysis of beta-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin-clavulanic acid. The CERIB Study Group.
J Antimicrob Chemother. 1995 Jul;36(1):267-9. doi: 10.1093/jac/36.1.267.
6
Frequency of inhibitor-resistant TEM beta-lactamases in Escherichia coli isolates from urinary tract infections in France.
J Antimicrob Chemother. 1994 Nov;34(5):707-14. doi: 10.1093/jac/34.5.707.
7
Identification of a novel plasmid-mediated beta-lactamase with chromosomal cephalosporinase characteristics from Klebsiella pneumoniae.
J Antimicrob Chemother. 1993 May;31(5):645-54. doi: 10.1093/jac/31.5.645.
8
Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli.
Antimicrob Agents Chemother. 1995 Feb;39(2):427-30. doi: 10.1128/AAC.39.2.427.
9
Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States.
Antimicrob Agents Chemother. 2004 May;48(5):1520-5. doi: 10.1128/AAC.48.5.1520-1525.2004.
10
Novel extended-spectrum TEM-type beta-lactamase from an Escherichia coli isolate resistant to ceftazidime and susceptible to cephalothin.
Antimicrob Agents Chemother. 1997 Mar;41(3):715-6. doi: 10.1128/AAC.41.3.715.
引用本文的文献
1
Analysis of the plasticity of location of the Arg244 positive charge within the active site of the TEM-1 beta-lactamase.
Protein Sci. 2009 Oct;18(10):2080-9. doi: 10.1002/pro.220.
2
Genetic and structural characterization of an L201P global suppressor substitution in TEM-1 beta-lactamase.
J Mol Biol. 2008 Dec 5;384(1):151-64. doi: 10.1016/j.jmb.2008.09.009. Epub 2008 Sep 16.
3
Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2008 Oct;52(10):3792-4. doi: 10.1128/AAC.00387-08. Epub 2008 Jul 28.
4
Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.
Antimicrob Agents Chemother. 2006 Sep;50(9):3179-82. doi: 10.1128/AAC.00218-06.
5
SHV-49, a novel inhibitor-resistant beta-lactamase in a clinical isolate of Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2004 Nov;48(11):4466-9. doi: 10.1128/AAC.48.11.4466-4469.2004.
6
Integration of a transposon Tn1-encoded inhibitor-resistant beta-lactamase gene, bla(TEM-67) from Proteus mirabilis, into the Escherichia coli chromosome.
Antimicrob Agents Chemother. 2003 Jan;47(1):19-26. doi: 10.1128/AAC.47.1.19-26.2003.
7
TEM-80, a novel inhibitor-resistant beta-lactamase in a clinical isolate of Enterobacter cloacae.
Antimicrob Agents Chemother. 2002 May;46(5):1183-9. doi: 10.1128/AAC.46.5.1183-1189.2002.
8
Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.
Antimicrob Agents Chemother. 2002 Mar;46(3):646-53. doi: 10.1128/AAC.46.3.646-653.2002.
9
TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3.
Antimicrob Agents Chemother. 2001 Dec;45(12):3591-4. doi: 10.1128/AAC.45.12.3591-3594.2001.
10
Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.
Clin Microbiol Rev. 2001 Oct;14(4):933-51, table of contents. doi: 10.1128/CMR.14.4.933-951.2001.
本文引用的文献
1
Extended-spectrum plasmid-mediated beta-lactamases.
J Antimicrob Chemother. 1995 Jul;36 Suppl A:19-34. doi: 10.1093/jac/36.suppl_a.19.
2
Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
Antimicrob Agents Chemother. 1993 Oct;37(10):2059-63. doi: 10.1128/AAC.37.10.2059.
3
Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.
Antimicrob Agents Chemother. 1994 May;38(5):1085-9. doi: 10.1128/AAC.38.5.1085.
4
Nucleotide sequences of the genes coding for the TEM-like beta-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2).
FEMS Microbiol Lett. 1994 Jul 1;120(1-2):75-80. doi: 10.1111/j.1574-6968.1994.tb07010.x.
5
Characterization and amino acid sequence of IRT-4, a novel TEM-type enzyme with a decreased susceptibility to beta-lactamase inhibitors.
FEMS Microbiol Lett. 1994 Jul 1;120(1-2):111-7. doi: 10.1111/j.1574-6968.1994.tb07016.x.
6
Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors.
J Antimicrob Chemother. 1994 Jun;33(6):1117-26. doi: 10.1093/jac/33.6.1117.
7
Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli.
Antimicrob Agents Chemother. 1995 Feb;39(2):427-30. doi: 10.1128/AAC.39.2.427.
8
Frequency of inhibitor-resistant TEM beta-lactamases in Escherichia coli isolates from urinary tract infections in France.
J Antimicrob Chemother. 1994 Nov;34(5):707-14. doi: 10.1093/jac/34.5.707.
9
Variations between the nucleotide sequences of Tn1, Tn2, and Tn3 and expression of beta-lactamase in Pseudomonas aeruginosa and Escherichia coli.
J Bacteriol. 1987 Feb;169(2):913-6. doi: 10.1128/jb.169.2.913-916.1987.
10
An efficient method for generating proteins with altered enzymatic properties: application to beta-lactamase.
Proc Natl Acad Sci U S A. 1989 Dec;86(23):9094-8. doi: 10.1073/pnas.86.23.9094.
Zotero 插件